Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Rebecca E Schweppe

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED
Phone303/724-3179
ORCID ORCID Icon0000-0001-7502-0151 Additional info

    Collapse Biography 
    Collapse education and training
    University of Colorado Health Sciences Center, Denver, COPhD 10/2000Biochemistry
    Gustavus Adolphus College, St. Peter, MNBA05/1994Biology
    University of Colorado Boulder, Boulder, COPostdoctoral fellowship05/2006Biochemistry and proteomics
    Collapse awards and honors
    2013Outstanding junior faculty "Rising Stars" Award, Department of Medicine, University of Colorado Anschutz Medical Campus
    2014Faculty Sponsor Award, University of Colorado Graduate School
    2014Environmental Health & Safety Merit Award for outstanding performance and dedication to lab safety, University of Colorado Anschutz Medical Campus
    2015 - 2019Director (Basic Science), American Thyroid Association
    2019 - 2020Leadership for Innovative Team Science (LITeS), Colorado CCTSI, University of Colorado Anschutz Medical Campus
    2020Dean's Doctoral Mentoring Award, University of Colorado Anschutz Medical Campus Graduate School

    Collapse Overview 
    Collapse overview
    The investigation of molecular mechanisms and targeted therapies is critical to help us understand the causes of thyroid cancer, how the tumor grows and spreads, and how we can find new ways to treat advanced disease for which there is currently no cure. The deregulation of protein kinases plays a major role in promoting tumorigenesis in the majority of human cancers, including thyroid cancer, and targeting this deregulated activity has led to major breakthroughs in cancer therapy. The goals of Dr. Rebecca Schweppe’s lab are to understand the regulation and function of deregulated kinase pathways in thyroid cancer in order to develop more effective therapies. We use translational approaches using cell lines derived from thyroid tumors to understand why some tumors are sensitive or resistant to different kinase-directed therapies, with the goal of identifying predictive biomarkers of response, and improving clinical responses. Ultimately, these studies will identify rational and more specific therapies for patients with advanced thyroid cancer.

    Collapse Research 
    Collapse research activities and funding
    R25CA240122     (REYLAND, MARY ELAINE)Sep 1, 2019 - Aug 31, 2025
    NIH
    Cancer Research Experiences for Undergraduates (CREU)
    Role: Co-Principal Investigator

    R01CA222299     (SCHWEPPE, REBECCA ELIZABETH)Jul 1, 2018 - Jun 30, 2023
    NIH
    Targeting FAK and Src in thyroid cancer
    Role: Principal Investigator

    RSG-13-060-01-TBE     (Rebecca E. Schweppe)Jan 1, 2013 - Dec 31, 2017
    American Cancer Society
    Targeting the Src Kinase Pathway in Thyroid Cancer
    Role: Principal Investigator

    R01CA164193     (SCHWEPPE, REBECCA ELIZABETH)Jul 1, 2012 - Apr 30, 2018
    NIH
    Targeting Focal Adhesion Kinase in Thyroid Cancer
    Role: Principal Investigator

    RC1 CA147371     (Bryan Haugen and James Fagin)Aug 31, 2011 - Aug 31, 2012
    NIH
    A validated resource of thyroid cancer cell lines for pathway discovery
    Role: Co-investigator

    F32GM065027     (SCHWEPPE, REBECCA E)Feb 1, 2002
    NIH
    The Regulation of the MAP Kinase Pathway and DNA Repair
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Rose MM, Nassar KW, Sharma V, Schweppe RE. AKT-independent signaling in PIK3CA-mutant thyroid cancer mediates resistance to dual SRC and MEK1/2 inhibition. Med Oncol. 2023 Sep 15; 40(10):299. PMID: 37713162.
      View in: PubMed
    2. Hicks HM, Pozdeyev N, Sams SB, Pugazhenthi U, Bales ES, Hofmann MC, McKenna LR, Schweppe RE. Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2. Mol Cancer Res. 2023 09 01; 21(9):867-880. PMID: 37219859.
      View in: PubMed
    3. Bolf EL, Beadnell TC, Rose MM, D'Alessandro A, Nemkov T, Hansen KC, Schweppe RE. Dasatinib and Trametinib Promote Anti-Tumor Metabolic Activity. Cells. 2023 05 12; 12(10). PMID: 37408209.
      View in: PubMed
    4. Rose MM, Espinoza VL, Hoff KJ, Pike LA, Sharma V, Hofmann MC, Tan AC, Pozdeyev N, Schweppe RE. BCL2L11 Induction Mediates Sensitivity to Src and MEK1/2 Inhibition in Thyroid Cancer. Cancers (Basel). 2023 Jan 06; 15(2). PMID: 36672327.
      View in: PubMed
    5. Nassar KW, Hintzsche JD, Bagby SM, Espinoza V, Langou?t-Astri? C, Amato CM, Chimed TS, Fujita M, Robinson W, Tan AC, Schweppe RE. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma. Mol Cancer Ther. 2021 10; 20(10):2049-2060. PMID: 34376578.
      View in: PubMed
    6. Pozdeyev N, Rose MM, Bowles DW, Schweppe RE. Molecular therapeutics for anaplastic thyroid cancer. Semin Cancer Biol. 2020 04; 61:23-29. PMID: 31991166.
      View in: PubMed
    7. Landa I, Pozdeyev N, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Genetics of Human Thyroid Cancer Cell Lines-Response. Clin Cancer Res. 2019 11 15; 25(22):6883-6884. PMID: 31732665.
      View in: PubMed
    8. Capes-Davis A, Bairoch A, Barrett T, Burnett EC, Dirks WG, Hall EM, Healy L, Kniss DA, Korch C, Liu Y, Neve RM, Nims RW, Parodi B, Schweppe RE, Storts DR, Tian F. Cell Lines as Biological Models: Practical Steps for More Reliable Research. Chem Res Toxicol. 2019 09 16; 32(9):1733-1736. PMID: 31203605.
      View in: PubMed
    9. Landa I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, Tan AC, Garcia-Rendueles MER, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies. Clin Cancer Res. 2019 05 15; 25(10):3141-3151. PMID: 30737244.
      View in: PubMed
    10. Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera DV, Landa I, Knauf JA, Fagin JA, Haugen BR. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. Mol Cancer Res. 2019 05; 17(5):1036-1048. PMID: 30733375.
      View in: PubMed
    11. Kessler BE, Mishall KM, Kellett MD, Clark EG, Pugazhenthi U, Pozdeyev N, Kim J, Tan AC, Schweppe RE. Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis. Oncogene. 2019 04; 38(14):2565-2579. PMID: 30531837.
      View in: PubMed
    12. Rosenthal MS, Angelos P, Schweppe RE. Research ethics dilemmas in thyroid disease. Curr Opin Endocrinol Diabetes Obes. 2018 10; 25(5):335-340. PMID: 30095478.
      View in: PubMed
    13. Oweida A, Phan A, Vancourt B, Robin T, Hararah MK, Bhatia S, Milner D, Lennon S, Pike L, Raben D, Haugen B, Pozdeyev N, Schweppe R, Karam SD. Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer. Thyroid. 2018 06; 28(6):739-747. PMID: 29774792.
      View in: PubMed
    14. Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, French JD, Borre PV, LaBarbera DV, Tan AC, Schweppe RE, Fishbein L, Ross JS, Haugen BR, Bowles DW. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clin Cancer Res. 2018 07 01; 24(13):3059-3068. PMID: 29615459.
      View in: PubMed
    15. Beadnell TC, Nassar KW, Rose MM, Clark EG, Danysh BP, Hofmann MC, Pozdeyev N, Schweppe RE. Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer. Oncogenesis. 2018 Feb 28; 7(2):23. PMID: 29487290.
      View in: PubMed
    16. Kiseljak-Vassiliades K, Zhang Y, Bagby SM, Kar A, Pozdeyev N, Xu M, Gowan K, Sharma V, Raeburn CD, Albuja-Cruz M, Jones KL, Fishbein L, Schweppe RE, Somerset H, Pitts TM, Leong S, Wierman ME. Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer. 2018 04; 25(4):437-451. PMID: 29371329.
      View in: PubMed
    17. Mishall KM, Beadnell TC, Kuenzi BM, Klimczak DM, Superti-Furga G, Rix U, Schweppe RE. Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer. Oncotarget. 2017 Nov 28; 8(61):103014-103031. PMID: 29262541.
      View in: PubMed
    18. Pozdeyev N, Yoo M, Mackie R, Schweppe RE, Tan AC, Haugen BR. Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies. Oncotarget. 2016 Aug 09; 7(32):51619-51625. PMID: 27322211.
      View in: PubMed
    19. Kessler BE, Sharma V, Zhou Q, Jing X, Pike LA, Kerege AA, Sams SB, Schweppe RE. FAK Expression, Not Kinase Activity, Is a Key Mediator of Thyroid Tumorigenesis and Protumorigenic Processes. Mol Cancer Res. 2016 09; 14(9):869-82. PMID: 27259715.
      View in: PubMed
    20. Beadnell TC, Mishall KM, Zhou Q, Riffert SM, Wuensch KE, Kessler BE, Corpuz ML, Jing X, Kim J, Wang G, Tan AC, Schweppe RE. The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer. Mol Cancer Ther. 2016 08; 15(8):1952-63. PMID: 27222538.
      View in: PubMed
    21. Chatterji T, Varkaris AS, Parikh NU, Song JH, Cheng CJ, Schweppe RE, Alexander S, Davis JW, Troncoso P, Friedl P, Kuang J, Lin SH, Gallick GE. Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells. Oncotarget. 2015 Apr 30; 6(12):10175-94. PMID: 25868388.
      View in: PubMed
    22. Morrison JA, Pike LA, Lund G, Zhou Q, Kessler BE, Bauerle KT, Sams SB, Haugen BR, Schweppe RE. Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models. Horm Cancer. 2015 Jun; 6(2-3):87-99. PMID: 25800363.
      View in: PubMed
    23. Henderson YC, Ahn SH, Ryu J, Chen Y, Williams MD, El-Naggar AK, Gagea M, Schweppe RE, Haugen BR, Lai SY, Clayman GL. Development and characterization of six new human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2015 Feb; 100(2):E243-52. PMID: 25427145.
      View in: PubMed
    24. Bauerle KT, Schweppe RE, Lund G, Kotnis G, Deep G, Agarwal R, Pozdeyev N, Wood WM, Haugen BR. Nuclear factor ?B-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8. J Clin Endocrinol Metab. 2014 Aug; 99(8):E1436-44. PMID: 24758177.
      View in: PubMed
    25. Plantinga TS, Heinhuis B, Gerrits D, Netea MG, Joosten LA, Hermus AR, Oyen WJ, Schweppe RE, Haugen BR, Boerman OC, Smit JW, Netea-Maier RT. mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2014 Jul; 99(7):E1368-75. PMID: 24712572.
      View in: PubMed
    26. Schweppe RE. Thyroid cancer cell line misidentification: an update. J Clin Endocrinol Metab. 2013 Mar; 98(3):956-7. PMID: 23472230.
      View in: PubMed
    27. Schweppe RE. Thyroid cancer cell lines: Critical models to study thyroid cancer biology and new therapeutic targets. Front Endocrinol (Lausanne). 2012; 3:81. PMID: 22723793.
      View in: PubMed
    28. Chan CM, Jing X, Pike LA, Zhou Q, Lim DJ, Sams SB, Lund GS, Sharma V, Haugen BR, Schweppe RE. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res. 2012 Jul 01; 18(13):3580-91. PMID: 22586301.
      View in: PubMed
    29. Wood WM, Sharma V, Bauerle KT, Pike LA, Zhou Q, Fretwell DL, Schweppe RE, Haugen BR. PPAR? Promotes Growth and Invasion of Thyroid Cancer Cells. PPAR Res. 2011; 2011:171765. PMID: 22194735.
      View in: PubMed
    30. Schweppe RE, Haugen BR. Thyroid targeted Kras(G12D)/Pten(-/-) mice and their cell lines: new tools to study thyroid cancer biology. Thyroid. 2011 Sep; 21(9):941-4. PMID: 21877921.
      View in: PubMed
    31. Bauerle KT, Schweppe RE, Haugen BR. Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion. Mol Cancer. 2010 May 21; 9:117. PMID: 20492683.
      View in: PubMed
    32. Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G. Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in BRAF Mutant Thyroid Carcinoma Cells. Endocr Rev. 2009 Dec 01; 30(7):932. PMID: 28199516.
      View in: PubMed
    33. Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M, Salvatore G. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab. 2010 Jan; 95(1):450-5. PMID: 19880792.
      View in: PubMed
    34. Schweppe RE, Kerege AA, Sharma V, Poczobutt JM, Gutierrez-Hartmann A, Grzywa RL, Haugen BR. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid. 2009 Aug; 19(8):825-35. PMID: 19500021.
      View in: PubMed
    35. Old WM, Shabb JB, Houel S, Wang H, Couts KL, Yen CY, Litman ES, Croy CH, Meyer-Arendt K, Miranda JG, Brown RA, Witze ES, Schweppe RE, Resing KA, Ahn NG. Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell. 2009 Apr 10; 34(1):115-31. PMID: 19362540.
      View in: PubMed
    36. Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL, Haugen BR. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab. 2009 Jun; 94(6):2199-203. PMID: 19293266.
      View in: PubMed
    37. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008 Nov; 93(11):4331-41. PMID: 18713817.
      View in: PubMed
    38. Schweppe RE, Cheung TH, Ahn NG. Global gene expression analysis of ERK5 and ERK1/2 signaling reveals a role for HIF-1 in ERK5-mediated responses. J Biol Chem. 2006 Jul 28; 281(30):20993-21003. PMID: 16735500.
      View in: PubMed
    39. Schweppe RE, Haydon CE, Lewis TS, Resing KA, Ahn NG. The characterization of protein post-translational modifications by mass spectrometry. Acc Chem Res. 2003 Jun; 36(6):453-61. PMID: 12809532.
      View in: PubMed
    40. Schweppe RE, Melton AA, Brodsky KS, Aveline LD, Resing KA, Ahn NG, Gutierrez-Hartmann A. Purification and mass spectrometric identification of GA-binding protein (GABP) as the functional pituitary Ets factor binding to the basal transcription element of the prolactin promoter. J Biol Chem. 2003 May 09; 278(19):16863-72. PMID: 12618435.
      View in: PubMed
    41. Tentler JJ, Bradford AP, Schweppe RE, Gutierrez-Hartmann A. Selective repression of rat prolactin gene by stable expression of dominant-negative Ets in GH4 pituitary cells. Endocrine. 2003 Feb-Mar; 20(1-2):3-12. PMID: 12668863.
      View in: PubMed
    42. Vaish NK, Dong F, Andrews L, Schweppe RE, Ahn NG, Blatt L, Seiwert SD. Monitoring post-translational modification of proteins with allosteric ribozymes. Nat Biotechnol. 2002 Aug; 20(8):810-5. PMID: 12118241.
      View in: PubMed
    43. Schweppe RE, Gutierrez-Hartmann A. Pituitary Ets-1 and GABP bind to the growth factor regulatory sites of the rat prolactin promoter. Nucleic Acids Res. 2001 Mar 01; 29(5):1251-60. PMID: 11222776.
      View in: PubMed
    44. Johnson TK, Schweppe RE, Septer J, Lewis RE. Phosphorylation of B-Myb regulates its transactivation potential and DNA binding. J Biol Chem. 1999 Dec 17; 274(51):36741-9. PMID: 10593981.
      View in: PubMed
    45. Schweppe RE, Frazer-Abel AA, Gutierrez-Hartmann A, Bradford AP. Functional components of fibroblast growth factor (FGF) signal transduction in pituitary cells. Identification of FGF response elements in the prolactin gene. J Biol Chem. 1997 Dec 05; 272(49):30852-9. PMID: 9388230.
      View in: PubMed
    Schweppe's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)